Amit Kumar, Chief Executive Officer at Anixa Biosciences Inc (ANIX), bought 3,188 shares at $3.37 ($11K) on 2026-07-27, disclosed to the SEC on 2026-07-27.
CEO Amit Kumar purchased 3,188 shares for $10,743.56 at $3.37, signaling confidence in the company's oncology pipeline and recent analyst upgrades. The trade coincides with the stock's strong 30-day rally and a Zacks Strong Buy rating.
The stock is up 24.41% over the last 30 days, trading at $3.44, which is 45.15% above its 52-week low of $2.37 but still down 36.96% from its high of $5.4566.
1) Zacks Rank upgrade to Strong Buy on July 22, 2026; 2) Advancement of breast cancer vaccine and CAR-T therapies, highlighted as a 'pivotal year' by CEO Amit Kumar in February 2026; 3) Planned Phase II study for the breast cancer vaccine.
The stock is currently trading at a forward P/E of -10.26, indicating potential profitability concerns, and has a short interest of 3.39% of the float.
Nothing distinguishes this filing.
| Filing → |
| ANIX | BUY | 2026-09-11 | $14K | — | Filing → |
| ANIX | BUY | 2026-08-03 | $17K | — | Filing → |
| ANIX | BUY | 2026-07-28 | $17K | — | Filing → |